Actavis is prohibited from launching a generic version of Quillivant XR until the expiration of the patent portfolio providing exclusivity in February 2031.
NCPA and 207 stakeholders are urging the Senate to pass legislation to empower the FTC to bring enforcement actions against the consolidated PBM-insurer industry and its anticompetitive practices, including spread pricing and clawbacks.
Triamcinolone acetonide injectable suspension is indicated for intramuscular and intra-articular use for multiple conditions including the treatment of various types of arthritis.